ArticleInternational journal of nanomedicine2016
The spherical nanoparticle-encapsulated chlorhexidine enhances anti-biofilm efficiency through an effective releasing mode and close microbial interactions.
Article in International journal of nanomedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Application and Potential of Local Drug Delivery Systems for Antibacterial Treatment of Periodontitis.International journal of molecular sciences · 2026Review
- Development of Solid Nanosystem for Delivery of Chlorhexidine with Increased Antimicrobial Activity and Decreased Cytotoxicity: Characterization and In Vitro and In Ovo Toxicological Screening.Molecules (Basel, Switzerland) · 2025Article
- The advancement of nanosystems for drug delivery in the prevention and treatment of dental caries.Frontiers in cellular and infection microbiology · 2025Review
- Strategies and mechanisms targetingFrontiers in cellular and infection microbiology · 2024Review
- Mouthwashes: Alternatives and Future Directions.International dental journal · 2023Review
- One-Pot Preparation of Cetylpyridinium Chloride-Containing Nanoparticles for Biofilm Eradication.ACS applied bio materials · 2023Article
- The application of mesoporous silica nanoparticles as a drug delivery vehicle in oral disease treatment.Frontiers in cellular and infection microbiology · 2023Review
- AntisenseInternational journal of nanomedicine · 2022Article
- Local Oral Delivery Agents with Anti-Biofilm Properties for the Treatment of Periodontitis and Peri-Implantitis. A Narrative Review.Molecules (Basel, Switzerland) · 2021Review
- Enhanced Antimicrobial Action of Chlorhexidine Loaded in Shellac Nanoparticles with Cationic Surface Functionality.Pharmaceutics · 2021Article
- Novel Strategies to Combat Bacterial Biofilms.Molecular biotechnology · 2021Review
- Recent Development of Active Ingredients in Mouthwashes and Toothpastes for Periodontal Diseases.Molecules (Basel, Switzerland) · 2021Review
- Impact of the antibiotic-cargo from MSNs on Gram-positive and Gram-negative bacterial biofilms.Microporous and mesoporous materials : the official journal of the International Zeolite Association · 2021Article
- Recent Advances Toward the Use of Mesoporous Silica Nanoparticles for the Treatment of Bacterial Infections.International journal of nanomedicine · 2021Review
- Eradication ofFrontiers in microbiology · 2021Article
- Dual antibacterial drug-loaded nanoparticles synergistically improve treatment of Streptococcus mutans biofilms.Acta biomaterialia · 2020Article
- Dealing with Skin and Blood-Brain Barriers: The Unconventional Challenges of Mesoporous Silica Nanoparticles.Pharmaceutics · 2018Review
- Novel Approaches to the Control of Oral Microbial Biofilms.BioMed research international · 2018Review
- Cellular Interactions and Formation of an Epithelial "Nanocoating-Like Barrier" with Mesoporous Silica Nanoparticles.Nanomaterials (Basel, Switzerland) · 2016Article
- Current trends and future prospects of chemical management of oral biofilms.Journal of oral biology and craniofacial researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We reported two forms (sphere and wire) of newly fabricated chlorhexidine (CHX)-loaded mesoporous silica nanoparticles (MSNs), and investigated their releasing capacities and anti-biofilm efficiencies. The interactions of the blank MSNs with planktonic oral microorganisms were assessed by field emission scanning electron microscopy. The anti-biofilm effects of the two forms of nanoparticle-encapsulated CHX were examined by 2,3-bis (2-methoxy- 4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide. The profiles of biofilm penetration were analyzed by fluorescent-labeled MSNs using confocal microscopy and ImageJ. The spherical MSNs with an average diameter of 265 nm exhibited a larger surface area and faster CHX-releasing rate than the MSN wires. The field emission scanning electron microscopy images showed that both shaped MSNs enabled to attach and further fuse with the surfaces of testing microbes. Meanwhile, the nanoparticle-encapsulated CHX could enhance the anti-biofilm efficiency with reference to its free form. Notably, the spherical nanoparticle-encapsulated CHX presented with a greater anti-biofilm capacity than the wire nanoparticle-encapsulated CHX, partly due to their difference in physical property. Furthermore, the relatively even distribution and homogeneous dispersion of spherical MSNs observed in confocal images may account for the enhanced penetration of spherical nanoparticle-encapsulated CHX into the microbial biofilms and resultant anti-biofilm effects. These findings reveal that the spherical nanoparticle-encapsulated CHX could preferably enhance its anti-biofilm efficiency through an effective releasing mode and close interactions with microbes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.